Effectiveness of a Combined Therapy With Paravertebral Oxygen-ozone Injections and Topical Patch Containing Cannabidiol and β-Caryophyllene for Treatment of Neck Pain: a Prospective, Randomized, Controlled Trial.

The aim of this study is to compare the effectiveness of combined treatment with paravertebral oxygen-ozone injections and topical patches containing Cannabidiol and β-Caryophyllene in patients with neck pain by evaluating the following aspects:
Reduction of pain
Reduction of disability associated with neck pain

开始日期2024-02-01

申办/合作机构

Humanitas Research Hospital

IRCT20180103038199N9 / Suspended临床2/3期IIT

Formulation and clinical evaluation (Phase 2 clinical trial) of complementary therapy with b-Caryophyllene in osteoarthritis patients: determination of effectiveness and safety

开始日期2023-11-22

申办/合作机构

Mashhad University of Medical Sciences

NCT06218407 / Completed临床1期

Development and Evaluation of Computerized Chemosensory Based Orbitofrontal Networks Training for Treatment of Pain (CBOT-P)

The overarching goal of this study phase, Phase I component is to configure Computerized Chemosensory-Based Orbitofrontal Networks Training (CBOT) into Computerized Chemosensory-Based Orbitofrontal Networks Training for Treatment of Pain CBOT-Pain (or CBOT-P) for rapid and sustained reduction of Pain, Negative Affect (NA) and Cognitive Impairments. The investigators aimed at first establishing if stimulation parameters targeting key olfactory regions, and their associated networks, paired with tasks that synergistically activate the orbitofrontal cortex (OFC) would have significantly different acute (< 7 days) effects in pain and NA intensity reductions. The hypothesis is that the short burst paradigm will more effectively activate the medial OFC and its functional connectivity with medial temporal affective networks, and result in greater reduction of affect and pain severity ratings after 7 days. The investigators will further examine if enhancing the odor regimen with beta-caryophyllene (BCP) content would have more dramatic effects in acute relief of pain, NA, and cognition.
Aim 1.1: To optimize CBOT-P stimulation parameters and olfactory stimulants for pain, affect and cognition in CP with and without high NA. This is a 14-day prospective study, in which fMRI and rs-fMRI will be acquired at baseline and day 7 during exposure to short vs long-burst CBOT stimulations. This is followed by daily treatment with short-burst versus long-burst CBOT paradigm over 14 days, during which pain and NA measures will be recorded daily by the subjects, and assessed by train research staff at baseline, day 7 and day 14.
Aim 1.2: To determine if CBOT regimen optimized with BCP content produces stronger and faster pain and affective response. This is a 14-day prospective study design, in which daily treatment of CBOT-PLUS (i.e., CBOT with BCP) will be compared against daily treatment with CBOT without BCP enhancement (CBOT). Subjects and clinicians are blinded to the assigned arms. Pain and NA measures will be recorded daily by the subjects and assessed by trained research staff at baseline and day 14.

开始日期2023-04-27

申办/合作机构

Evon Medics LLC

[+3]

100 项与 β-石竹烯相关的临床结果

登录后查看更多信息

100 项与 β-石竹烯相关的转化医学

登录后查看更多信息

100 项与 β-石竹烯相关的专利（医药）

登录后查看更多信息

1,144

项与 β-石竹烯相关的文献（医药）

2024-12-01·FOOD CHEMISTRY

Identification of characteristic compounds of sweet orange oil and their sweetening effects on the sucrose solution with sweetness meter, sensory analysis, electronic tongue, and molecular dynamics simulation

Article

作者: Xiao, Zuobing ; Niu, Yunwei ; Zhu, Jiancai ; Zhang, Jing ; Zhou, Rujun ; Zhao, Liming

The characteristic aroma compounds of five-fold sweet orange oil were analyzed using gas chromatography-mass spectrometry combined with the odor aroma value (OAV) method. The results indicated that limonene, linalool, dodecanol, (E,E)-2,4-decadienal, (E)-citral, linalool, (E)-2-decenal, and geraniol are important contributors. The sweetening effects of key compounds on sucrose solutions were experimentally investigated. The results showed that the sweetness effects of five compounds (limonene, citronellal, geraniol, β-sinensal and β-caryophyllene) were better than those of (E)-citral, linalool and octanal. Molecular dynamics implied that the hydrogen bonding residues of the T1R2/T1R3-sucrose system were converted from LYS65, GLU302, ASP278, and SER144 to ASP278, SER144, ASP142, and ASP213 after the addition of limonene. Meanwhile, the hydrophobic interaction forces of the system are significantly enhanced. The total energy of the T1R2/T1R3-sucrose system decreased from -32.08 kcal/mol to -63.57 kcal/mol. The synergistic sweetening mechanism of characteristic aroma compounds of sweet orange oil on sucrose was revealed.

2024-12-01·BIOPROCESS AND BIOSYSTEMS ENGINEERING

Biosynthesis and biological activities of magnesium hydroxide nanoparticles using Tinospora cordifolia leaf extract

Article

作者: Althobaiti, Norah A ; Alfaifi, Mohammad Y ; Shati, Ali A ; Rajkumar, Manickam ; Gomathi, Thandapani ; Albalawi, Aishah E ; Presley, S I Davis ; Kirubakaran, Dharmalingam ; Menaa, Farid ; Govindaraj, Prabha ; Elbehairi, Serag Eldin I ; Meenambigai, Krishnan

The synthesis of magnesium hydroxide nanoparticles (Mg(OH)₂ NPs) using plant extracts are known to be a practical, economical, and an environmentally friendly approach. In this work, Mg(OH)₂ NPs were synthesized using aqueous leaf extract of Tinospora cordifolia, a medicinal plant commonly found in India. The synthesized Mg(OH)₂ NPs were characterized using various spectroscopic techniques. The ultraviolet-visible (UV-Vis) absorption peak of the Mg(OH)₂ NPs was detected at 289 nm, Fourier transform infrared (FTIR) analysis confirmed the presence of various functional groups, and X-ray diffraction (XRD) patterns revealed the well-crystallized structure of the Mg(OH)₂ NPs. High-resolution transmission electron microscopy (HR-TEM) and scanning electron microscopy (SEM) analyses depicted spherical morphology and an average particle size (PS) of 27.71 nm. The energy-dispersive X-ray (EDX) analysis confirmed the presence of C, O, and Mg elements, and the X-ray photoelectron spectroscopy (XPS) survey spectrum confirmed the elements for the Su 1 s peak at 280.2 eV. The dynamic light scattering (DLS) analysis displayed an average PS of 54.3 nm, and the Zeta potential (ZP) was of 9.89 mV. The fabricated Mg(OH)₂ NPs displayed notable antibacterial activity against S. epidermidis, E. coli, and S. aureus. In addition, these NPs exhibited strong antioxidant properties (> 75%) based on DPPH, ABTS, and hydrogen peroxide (H₂O₂) assays. Further, the same NPs exerted a potent anti-inflammatory activity (> 65%) based on COX-1 and COX-2 evaluations. The anti-Alzheimer' disease (AD) potential of Mg(OH)₂ NPs was assessed through effective inhibition (> 70%) of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) activities. Molecular docking (MD) studies confirmed that caryophyllene has higher binding affinity with AChE (-5.3 kcal/mol) and BuChE (-6.4 kcal/mol) enzymes. This study emphasizes the green synthesis of Mg(OH)₂ NPs using T. cordifolia as a plant source and highlights their potential for biomedical applications.

2024-11-01·INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

Unravelling the genomic landscape reveals the presence of six novel odorant-binding proteins in whitefly Bemisia tabaci Asia II-1

Article

作者: Nebapure, S.M. ; Gouda, M.N. Rudra ; Naga, Kailash Chandra ; Nebapure, S M ; Subramanian, S ; Gouda, M N Rudra ; Subramanian, S.

Genome wide analysis identified 14 OBPs in B. tabaci Asia II-1, of which six are new to science. Phylogenetic analysis traced their diversity and evolutionary lineage among Hemipteran insects. Comparative analysis reclassified the OBP gene families among B. tabaci cryptic species: Asia I, II-1, MEAM1, and MED. The 14 OBPs were clustered on four chromosomes of B. tabaci. RT-qPCR showed high expression of OBP3 and 8 across all body tissues and OBP10 in the abdomen. Molecular docking showed that OBP 3 and 10 had high affinity bonding with different candidate ligands, with binding energies ranging from -5.0 to -7.7 kcal/mol. Competitive fluorescence binding assays revealed that β-caryophyllene and limonene had high binding affinities for OBP3 and 10, with their IC50 values ranging from 9.16 to 14 μmol·L-1 and KD values around 7 to 9 μmol·L-1. Behavioural assays revealed that β-caryophyllene and carvacrol were attractants, β-ocimene and limonene were repellents, and γ-terpinene and β-ocimene were oviposition deterrents to B. tabaci. Functional validation by RNAi demonstrated that OBP3 and OBP10 modulated host recognition of B. tabaci. This study expands our understanding of the genomic landscape of OBPs in B. tabaci, offering scope for developing novel pest control strategies.

项与 β-石竹烯相关的新闻（医药）

2024-04-10

·GlobeNewswire-Health Care

Avicanna Announces Completion of Topical Gel Observational Real-World Evidence Study

The study results revealed improvements in symptoms and quality of life in patients with musculoskeletal pain and inflammationTORONTO, April 10, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce the completion of its observational real-world evidence (“RWE”) study using RHO Phyto branded cannabigerol (“CBG”) transdermal gel on patients with musculoskeletal pain and inflammation. The RWE study evaluated patient-reported efficacy of the RHO Phyto CBG Transdermal Gel containing 2% cannabidiol (“CBD”) and 1% CBG on a range of clinical conditions including arthritis, osteoarthritis, rheumatoid arthritis, fibromyalgia, muscle and joint pain, localized pain, muscular and structural injuries, and post-surgical pain. Seventy-one participants completed baseline testing and a follow up at one month including demographic, medical history, medication use and two standardized symptom questionnaires. The RWE study revealed a meaningful improvement in overall Musculoskeletal Health Questionnaire scores (p<0.001) as compared from baseline to one month. Specifically, there was a reported 35.4% improvement in health-related domains including symptoms, physical functioning, daily activities and work, physical well-being, and confidence to manage symptoms. In addition, evaluation of the Edmonton Symptom Assessment System questionnaire also revealed an improvement in pain, sleep, anxiety, and well-being symptoms from baseline to one month (p<0.001). “The preliminary result of this study is in line with the reported results of our products with Canadian patients providing valuable insight for our next stages of clinical development. In parallel, this will propel our efforts under medical cannabis or cosmetic legislation internationally,” stated Dr. Karolina Urban, Executive Vice President Medical Affairs. The RWE study participants with an average age of 58 ± 15 (64% women) all presented with symptoms of chronic pain. According to ICD-10 diagnosis classification, 21.1% of participants had a diagnosis related to arthritis (polyarthritis, osteoarthritis, etc.), 17.5% of participants with a diagnosis of dorsalgia, 12.3% with fibromyalgia, and 8% with chronic intractable pain. Prior to initiation of the study, study participants reported they were taking an average of ten medications including NSAIDs, opioids, antidepressants, or skeletal muscle relaxants. Each RWE study participant was assigned a common treatment plan of a combination of a CBD oil (83.3%) or balance oil (16.7%) with the RHO Phyto CBG Transdermal Gel. About the RHO Phyto Transdermal CBG Gel The CBG Transdermal Gel is a part of Avicanna’s RHO Phyto formulary of medical products which includes proprietary oral, sublingual, and topical products containing a range of cannabinoids. The gel includes a combination of CBG and CBD in a fast-absorbing, water-based gel intended for application locally to area of focus. The gel utilizes Avicanna’s deep tissue emulsion technology and combines cannabinoids with synergistic natural ingredients and terpenes including menthol, eugenol and beta-caryophyllene. About Avicanna Inc. Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of cannabinoid-based products and formulations for the global medical and pharmaceutical market segments. Avicanna has an established scientific platform including R&D and clinical development leading to the commercialization of more than thirty proprietary, evidence-based finished products and supporting four commercial-stage business pillars. Medical Cannabis formulary (RHO Phyto™): The formulary offers a diverse range of proprietary products including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids, supported by ongoing patient, and medical community education. RHO Phyto is an established leading medical brand in Canada currently available nationwide to patients across several medical channels and continues to expand into new international markets. Medical cannabis care platform (MyMedi.ca): MyMedi.ca is a medical cannabis care platform formed with the aim to better serve medical cannabis patients’ needs and enhance the patient journey. MyMedi.ca is operated by Northern Green Canada Inc. and features a diverse portfolio of products and bilingual pharmacist-led patient support programs. MyMedi.ca also provides specialty services to distinct patient groups such as veterans and collaborates with public and private payers for adjudication and reimbursement. MyMedi.ca provides educational resources to the medical community to facilitate the incorporation of medical cannabis into health care regimens. Pharmaceutical products (Trunerox™) and pipeline: Leveraging Avicanna’s scientific platform, vertical integration, and real-world evidence, Avicanna has developed a pipeline of proprietary, indication-specific pharmaceutical products that are in various stages of clinical development and commercialization. These cannabinoid-based drug candidates aim to address unmet medical needs in the areas of dermatology, chronic pain, and various neurological disorders. Avicanna’s first indication-specific pharmaceutical drug, Trunerox™, was approved Q1 2024 by the Health Authority of Colombia INVIMA as an adjuvant treatment for seizures associated with Lennox-Gastaut Syndrome and Dravet Syndrome. Active pharmaceutical ingredients (Aureus Santa Marta™): Active pharmaceutical ingredients (“API”) supplied by the Company’s majority owned subsidiary Santa Marta Golden Hemp SAS (“SMGH”) is a commercial-stage business dedicated to providing a various forms high-quality CBD, THC and CBG to the Company’s international partners for use in the development and production of food, cosmetics, medical, and pharmaceutical products. The business unit also forms part of the Company’s supply chain and is a source of reliable input products for its consumer retail, medical cannabis, and pharmaceutical products for globally. SOURCE Avicanna Inc. Stay Connected For more information about Avicanna, visit our website, contact Ivana Maric by email at info@avicanna.com or follow us on social media on LinkedIn, Twitter, Facebook, or Instagram. The Company posts updates through videos from the Company YouTube channel. Cautionary Note Regarding Forward-Looking Information and Statements This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information contained in this news release may be identified using words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions. Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include but are not limited to current and future market conditions, including the market price of the common shares of the Company, and the risk factors set out in the Company’s annual information form dated April 1, 2024 filed with the Canadian securities regulators and available under the Company’s profile on SEDAR at www.sedar.com. The statements in this news release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws. A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/fab77b86-bdad-4cda-8307-dba91631e46c

临床结果上市批准

2024-01-24

·PRNewswire

CANOPY GROWTH KICKS OFF THE NEW YEAR WITH NEW PRODUCTS FROM TWEED, 7ACRES, AND SPECTRUM THERAPEUTICS

SMITHS FALLS, ON, Jan. 24, 2024 /PRNewswire/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX: WEED) (Nasdaq: CGC), a world-leading diversified cannabis company, today announced the introduction of new product offerings across the Company's adult use and medical cannabis portfolio, including new Tweed softgels and oils featuring minor cannabinoids, a large format flower offering from Tweed, as well as new medical exclusive pre-roll products from 7ACRES and Spectrum Therapeutics. "In addition to launching new flower products, we're making it easier to access CBD and minor cannabinoids in convenient oil and softgel formats to support wellness-minded consumers looking to start the year feeling their best," said Dave Paterson, President, Canada, Canopy Growth. "For our medical cannabis consumers, we're proud to continue delivering the variety and convenience that the Spectrum Therapeutics store is synonymous for thanks to new pre-rolls from 7ACRES and the Spectrum Reserve." Tweed Lemon Meringue Pie flower For consumers not wanting to compromise quality for quantity, Tweed Lemon Meringue Pie is being served up fresh in a large format 28g package. Packed with sativa whole cannabis flower which has been derived from the Lemon Skunk and Cookies 'n' Cream lineage, it features terpenes a-Pinene, Myrcene and Limonene. Tweed's Lemon Meringue Pie boasts lemon, citrus and nutty vanilla aromas, is hang-dried, and comes in with a 23-29% THC range. Grown in our Kincardine, Ontario facility and packaged with a Boveda humidity control pack to ensure freshness, this new flower offering is full of flavour just like lemon meringue should be. 7ACRES Jack Haze pre-rolls 7ACRES Jack Haze pre-rolled joints are arriving in a 0.5gx14 large pack and feature the famous sativa-dominant cultivar with a unique combination of sweet citrus, crisp pine, and warm spice notes. With a range of 17-23% THC and a max CBD potency of 25%, 7ACRES Jack Haze was the result of a large-scale genetic selection program with the goal of finding this novel sativa expression. This phenotype stood out among the rest as it possessed both the sweet haze notes characteristic of a haze cultivar, along with a distinct spice aroma. Spectrum Reserve pre-rolls Exclusive for medical cannabis customers, Spectrum Therapeutics is extending its Spectrum Reserve collection with Alien Breath and (GG#4 x Mendo Breath) pre-roll joints. Coming in a 0.5gx10 large pack of pre-rolls, this hybrid strain delivers a high 22-28% THC range. The flower's berry, fruity, nutty, sour, and chemical notes derive from its Alien Breath and (GG#4 x Mendo Breath) lineage and its terpenes include 3.5% β-Caryophyllene, 6% D-Limonene, 6.5% Beta Myrcene, and 10% Pinene (Alpha & Beta). With consumer needs top of mind, Tweed has also introduced four new products featuring CBD and minor cannabinoids in both oil and softgel formats. Tweed CBD:CBG 4:1 Oil A newly formulated cannabis oil arriving in a 30mL bottle, Tweed CBD:CBG 4:1 is designed to pair with well-being focused daily routines and provides 100 mg/g CBD and 25 mg/g CBG. Tweed CBD:CBG 6:1 Softgels For those who prefer the convenience and portability of the softgel format, Tweed CBD:CBG 6:1 is available with 30 softgels per bottle each containing 60 mg of CBD and 10 mg CBG. Tweed CBD:CBN 4:1 Oil Coming in a 30mL oil format, the Tweed CBD:CBN 4:1 oil offering is designed to become part of a nightly routine and delivers 100 mg/g CBD and 25 mg/g CBN. Tweed CBD:CBN 6:1 Softgels Another win for those who prefer the convenience of softgels, Tweed CBD:CBN 6:1 is available with 30 softgels per bottle each containing 60 mg of CBD and 10 mg CBN. Tweed oil and softgel products are made with non-GMO, coconut derived MCT oil and blended cannabis extracts. All Tweed offerings are available for purchase via legal recreational cannabis e-commerce channels and retail locations in select regions. 7ACRES and Spectrum products are available for purchase online at spectrumtherapeutics.com. For more information, please visit Tweed and Spectrum Therapeutics. Disclaimer: Terpene amounts may vary on a per-lot basis due to the natural variability of cannabis plants. THC and CBD ranges may vary. See product packaging for accurate levels. Everyone experiences cannabis differently. About Canopy Growth Canopy Growth is a leading North American cannabis and consumer packaged goods ("CPG") company dedicated to unleashing the power of cannabis to improve lives. Through an unwavering commitment to our consumers, Canopy Growth delivers innovative products with a focus on premium and mainstream cannabis brands including Doja, 7ACRES, Tweed, and Deep Space. Canopy Growth's CPG portfolio includes gourmet wellness products by Martha Stewart CBD, and category defining vaporizer technology made in Germany by Storz & Bickel. Canopy Growth has also established a comprehensive ecosystem to realize the opportunities presented by the U.S. THC market through its rights to Acreage Holdings, Inc., a vertically integrated multi-state cannabis operator with principal operations in densely populated states across the Northeast, as well as Wana Brands, a leading cannabis edible brand in North America, and Jetty Extracts, a California-based producer of high-quality cannabis extracts and pioneer of clean vape technology. Beyond our world-class products, Canopy Growth is leading the industry forward through a commitment to social equity, responsible use, and community reinvestment—pioneering a future where cannabis is understood and welcomed for its potential to help achieve greater wellbeing and life enhancement. For more information visit References to information included on, or accessible through, our website do not constitute incorporation by reference of the information contained at or available through our website, and you should not consider such information to be part of this press release. SOURCE Canopy Growth Corporation

2023-04-20

·GlobeNewswire-Health Care

Celebrate 420 with Good Supply!

Enjoy a Blast of Summer Nostalgia with Good Supply’s New Product Lineup Now Available Across CanadaTORONTO, April 19, 2023 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray" or the "Company") (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis-lifestyle and consumer packaged goods company, announced today the launch of their latest product lineup from its best-selling Canadian cannabis brand, Good Supply1. In celebration of this year’s upcoming 420 holiday, Good Supply is introducing a range of new products, including pre-rolls, flower, and vapes, available in select provinces across Canada. Good Supply’s latest product lineup for 420 includes: Rocket Bomb 510 Vape Cartridge: Inspired by a timeless classic, the Rocket Bomb vapes embrace fruit-forward aromas, a proprietary blend of terpenes, and powerful potency levels. Available in British Columbia, Alberta, Manitoba, Saskatchewan, and Ontario, in 1G. Lava Fuel Whole Flower: Lava Fuel is a breezy and cerebral hybrid with a focus on diesel, earthy, and floral aromas. The exotic lineage of Aspen OG x High Country Diesel gives trichome-dense flower overflowing with caryophyllene, limonene, and myrcene. Fill up with Lava Fuel, now available in Alberta in 3.5g. Grandpa's Stash Pre-Rolls and Whole Flower: Grandpa’s Stash is sweet and spicy hybrid-leaning sativa derived from its Super Skunk x OG Kush x Afghan Kush cross and dominant terpenes of caryophyllene, humulene, limonene. Enjoy Grandpa’s Stash whenever the mood strikes. Available now in Alberta in 3.5g Whole Flower and 10x.35g Pre-Rolls, and available in British Columbia, Manitoba, and Saskatchewan in 28g Whole Flower and 10x.35g Pre-Rolls, while later this summer, *Grandpa’s Stash is coming to Ontario Summer 2023 in 28g. _______________1 Produced in accordance with Health Canada Processing and Cultivation licence by Aphria Inc., a subsidiary of Tilray Brands, Inc. To get consumers excited for the summer, the following will also be released post-420: Frozen Watermelon 510 Vape Cartridge: Packed with watermelon aromas and topped off with a slight cooling sensation, Good Supply’s new Frozen Watermelon Vapes are making their debut. This May, in addition to the new Rocket Bomb vapes, the new Good Supply Frozen Watermelon vapes will also be available in Alberta, Manitoba, Saskatchewan, and Ontario in 1G. Monkey Butter 14 x 0.5g Pre-Rolls: Consumers love some of the traditional “joint” experiences provided by Good Supply. Previously released earlier this year in whole flower, the brand’s new processes now allow them to bring the consistency of Good Supply pre-rolls to a convenient 14-pack, produced for the avid daily cannabis user. Available in Ontario in 14x0.5g coming this May. “We’re thrilled to offer Canadians a new product lineup for the season,” said Michelle Morin, Senior Brand Manager at Tilray Brands. “Continuing to offer our consumers new & exciting options within our core product lines allows them to explore new sensations and flavours with the consistency, quality and value they’ve come to expect from Good Supply. With a whole array of new products added to this year’s lineup, we’re proud to be able to give our Good Supply fans more offerings that they’re sure to love.” Good Supply's latest product offerings are now available at select retailers in provinces and markets across Canada. To learn more about the brand and its new products, follow @goodsupplycannabis on Instagram and @goodsupplycan on Twitter. About Good Supply Good Supply is one of Canada's leading cannabis brands in flower, pre-rolls, vapes, concentrates, and has become a favourite among consumers and budtenders. At Good Supply good is the new great. Rooted in classic strains that punch above their weight, Good Supply has been one of the top-selling brands in the concentrates and pre-roll category within Canada and is known for its innovative take on its products across its expansive portfolio. To learn more about Good Supply, visit www.goodsupplycannabis.com and follow @goodsupplycannabis. About Tilray BrandsTilray Brands, Inc. (Nasdaq: TLRY and TSX: TLRY) is a leading global cannabis-lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America that is changing people’s lives for the better – one person at a time – by inspiring and empowering the worldwide community to live their very best life by providing them with products that meet the needs of their mind, body, and soul and invoke a sense of wellbeing. Tilray’s mission is to be the trusted partner for its patients and consumers by providing them with a cultivated experience and health and wellbeing through high-quality, differentiated brands and innovative products. A pioneer in cannabis research, cultivation, and distribution, Tilray’s unprecedented production platform supports over 20 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and alcoholic beverages. For more information on Tilray, visit Tilray Brands, Inc. and follow @tilray on Instagram, Twitter, Facebook, and LinkedIn. Forward-Looking StatementsCertain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections, or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses, or current expectations concerning, among other things, the Company’s ability to commercialize new and innovative products worldwide. Many factors could cause actual results, performance, or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Tilray and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities laws. Contacts:Media:Kaitlin Macapagalnews@tilray.comInvestors:Raphael Gross203-682-8253Raphael.Gross@icrinc.com

100 项与 β-石竹烯相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
慢性疼痛	临床2期	美国	Hartford Hospital, Inc.	2021-09-30
药物滥用	临床1期	美国	National Center for Complementary and Integrative Health	2021-12-15
疼痛	临床1期	美国	National Center for Complementary and Integrative Health	2021-12-15
糖尿病心肌病	临床前	阿拉伯联合酋长国	United Arab Emirates University	2024-07-02